Patient Persistence to OnabotulinumtoxinA Treatment for Overactive Bladder Using a Reduced Injection-Site Paradigm: A...

Area of Science:

• Urology
• Pharmacology
• Clinical Medicine

Background:

• OnabotulinumtoxinA (onabotA) is an established treatment for overactive bladder (OAB).
• Standard treatment protocols may involve multiple injection sites.
• A reduced injection-site paradigm offers a potentially more convenient administration method.

Purpose of the Study:

• To evaluate treatment persistence in patients with overactive bladder (OAB) receiving onabotA (100 U) with a reduced injection-site paradigm (≤3 sites).
• To assess the safety and efficacy of this modified administration approach.

Main Methods:

• Retrospective chart review of adult female OAB patients refractory to prior treatments.
• OnabotA (100 U) administered via 1-3 injections between July 2017 and June 2021.
• Persistence defined as ≥3 treatments within the study period; adverse events and patient-reported outcomes were documented.

Main Results:

• 61.1% of patients (55/90) demonstrated treatment persistence, completing at least 3 treatments.
• Urinary tract infection (UTI) occurred after 4.9% of treatments (18/370), with 16.7% of patients reporting UTI overall.
• No patients required clean intermittent catheterization due to UTI.

Conclusions:

• A reduced injection-site paradigm for onabotA in OAB treatment achieved a 61.1% persistence rate.
• The reduced injection-site method did not introduce new safety concerns.
• Results may have limited generalizability due to small sample sizes at later timepoints.